UK’s Autolus Therapeutics to raise $125 mln in initial public offering

UK biopharmaceuticals company Autolus Therapeutics has planned to raise $125 million in an initial public offering.

Autolus Therapeutics will issue 7,800,000 shares at a price of $15.00-$17.00 per share. U.S. investment bank and financial services company Goldman Sachs and peer Jefferies served as the underwriters for the listing and other peers Wells Fargo Securities and William Blair were co-managers.

In the last 12 months, the company generated $1.7 million in revenue and has a market capitalisation of $604.4 million.

Autolus Therapeutics said that using its broad suite of proprietary and modular T-cell programming technologies, it is engineering precisely targeted, controlled and highly active T-cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.